Amniotic membrane allograft receives HCPCS C-Code from Medicare
MiMedx Group, Inc (Kennesaw, GA) received a transitional pass-through status C-Code from the Centers for Medicare & Medicaid Services for its EpiFix® Amniotic Membrane Allograft. It has been assigned a pass-through status under Medicare's outpatient prospective payment system effective January 1, 2012. This code will facilitate reimbursement for the application of the product when used in Medicare patients with chronic wounds. This code will cover the grafts used in treating Medicare patients with dermal wounds in the hospital operating room or a freestanding surgical suite.
For more information, visit www.mimedx.com